Lesson from a metastatic male breast cancer case: CDK4/6 plus aromatase inhibitors could not exceed tamoxifen
Abstract Male breast cancer (MaBC) is a rare disease, and treatment approaches are often extrapolated from female breast cancer protocols. We present the case of a 55-year-old male diagnosed with estrogen receptor-positive metastatic breast cancer who exhibited primary resistance to first-line treat...
Saved in:
| Main Authors: | Tala Najdi, Samah Seif, Nahed Damaj, Joseph Kattan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-05-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02571-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative study of the efficacy of tamoxifen and aromatase inhibitors among breast cancer patients at Kenyatta National Hospital
by: Henry Gachoki Macharia, et al.
Published: (2025-08-01) -
Cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early oestrogen receptor-positive breast cancer: a systematic review
by: Ying X. Gue, et al.
Published: (2024-07-01) -
Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning
by: Oana Maria Burciu, et al.
Published: (2025-07-01) -
Selective estrogen receptor modulators and aromatase inhibitors in the treatment of functional male hypogonadism
by: Jakub Wydra, et al.
Published: (2025-08-01) -
Estrogen/androgen balance in men with hyperestrogenism normalized by using letrozole of the aromatase inhibitor drug class
by: Z. Sh. Pavlova, et al.
Published: (2022-03-01)